Fixed-Dose Inotuzumab Produces Deep Early Responses in B-ALL

Company Qingdao University Event Type Published Research (Prospective Clinical Study) Modality CD22-directed antibody-drug conjugate Asset Inotuzumab ozogamicin (fixed-dose regimen) Target CD22 Disease Area B-cell acute lymphoblastic leukemia (B-ALL), newly diagnosed Summary A 39-patient prospective study from Qingdao University reported high remission and MRD-negativity rates with…